1. Introduction {#sec1}
===============

The majority of bladder cancers are epithelial in origin \[[@B1], [@B2]\]. Lymphomas of the urinary bladder are exceedingly rare and can be divided into (i) primary, a rare lymphoma arising in the urinary bladder with no evidence of lymphoma elsewhere, or (ii) secondary lymphoma of the urinary bladder associated with lymphoma at an extra vesicle site \[[@B3], [@B4]\]. Primary malignant lymphoma of the bladder accounts for less than 1% of neoplasms unlike secondary lymphoma, which is much more common \[[@B1], [@B2]\]. Of primary lymphomas of the bladder, mucosa associated lymphoid tissue lymphoma, or MALT, is the most prevalent histological subtype. The optimal treatment of primary MALT confined to the bladder remains to be defined. Here, we report a patient treated with definitive radiation and review the relevant literature to better define the optimal management of this rare disease.

2. Case Report {#sec2}
==============

A 65-year-old female presented to her gynecologist after she noted a two-week history of spotting on toilet paper after urinating. She was referred to a urologist for further investigation of the bladder lesion. A transurethral resection of the bladder tumor (TURBT), with resection of the posterior bladder wall, right bladder wall, and bladder neck, was performed at an outside hospital. Initial pathology based on H&E stain and immunohistochemistry favored extra nodal marginal zone lymphoma with follicular colonization, with cells positive for CD20 and PAX-5 and negative for CD5 and CD10 ([Figure 1](#fig1){ref-type="fig"}). Laboratory evaluation including LDH, B2-microglobulin, serum immunofixation, and protein electrophoresis was all within normal limits. Subsequently, the patient underwent a PET/CT and bone marrow biopsy, and there was no evidence of any extra vesicular disease.

The patient was referred to radiation oncology to discuss the role of definitive radiation in her treatment regimen. Magnetic resonance imaging and repeat cystoscopy were recommended and performed to assess the presence of residual disease and were both negative. A well-healed biopsy area was noted on cystoscopy consistent with the site of original lesion. At this time, the patient\'s hematuria was resolved and she denied any weight loss, fatigue, night sweats, or fevers. The patient had no history of recurrent sexually transmitted diseases. There was no lymphadenopathy, organomegaly, or abnormal findings on physical examination.

Based on patient\'s lack of symptoms, negative imaging, and negative repeat cystoscopy, the patient was offered a course of close observation with serial cystoscopic evaluations versus definitive radiation given that the presence of microscopic disease could not be ruled out. She elected to proceed with radiation therapy. The patient received a total dose of 30 Gy in 20 equal daily fractions with a 4-field 3D-CRT plan utilizing PH16 MV photons. The adjacent normal structures were shielded with a multileaf collimator (MLC) ([Figure 2](#fig2){ref-type="fig"}). The patient tolerated radiation treatment well. She had no gastrointestinal, urinary, or gynecological toxicities during treatment and at short interval follow-up. Repeat evaluation 3 months following radiation with PET/CT revealed no evidence of disease and urine cytology was also negative.

3. Discussion {#sec3}
=============

Primary lymphoma of the bladder is a rare malignancy, with limited literature to guide therapy. The first ever reported case of bladder lymphoma was reported in the literature by Eve and Chaffey in 1885 \[[@B4]--[@B8]\]. There have been less than 100 cases described in the literature since \[[@B4], [@B9], [@B10]\]. The disease typically presents in the 6th decade of life with slight predominance in females \[[@B6], [@B10]\]. Since lymphoid tissue is not found in the urinary bladder, chronic inflammation is postulated as the origin. As such, most patients present with symptoms of chronic cystitis \[[@B9]\]. However, similar to our patient, there have been many reported cases in which chronic cystitis and histological evidence of inflammation are lacking \[[@B4], [@B6], [@B11], [@B12]\]. The most common symptoms of lymphoma of the urinary bladder include weight loss, fatigue, hematuria, dysuria, nocturia, urinary frequency, and suprapubic or abdominal pain \[[@B4], [@B11], [@B12]\]. [Table 1](#tab1){ref-type="table"} contains a summary of basic patient demographics, presenting symptoms, treatments, and outcomes of all reported cases of primary MALT lymphoma of the bladder.

There are many treatment options for nongastric MALT lymphomas: (i) observation (based on factors such as patient age, risk factors, and tumor grade, observation might be the best option \[[@B11]\]); (ii) surgery (complete excision or biopsy) (MALT lymphomas that are unifocal can be partially or completely removed with procedures like TURBT \[[@B11]\]); (iii) radiation (radiation, when given alone or after an excisional biopsy, has shown excellent local control and improved overall disease-free survival \[[@B10], [@B13]--[@B15]\]); (iv) chemotherapy (usually used when a patient presents with systemic involvement or secondary lymphoma of the bladder \[[@B16]--[@B18]\]); (v) targeted antibody therapy (anti-CD20 antibody (rituximab) has been used along with other modalities in systemic lymphomas \[[@B17], [@B19]\]); (vi) antibiotics (they are usually used in cases where there is a known bacterial origin such as*H. pylori* in the stomach). There have been rare cases where antibiotics were used for MALT lymphomas of the bladder \[[@B20]\].

The presentation of bladder MALT lymphoma is exceedingly rare; however, MALT lymphomas at other sites are common, especially in the GI tract, salivary gland, lung, Waldeyer\'s ring, ocular adnexa, skin, thyroid, and breast. These lymphomas are highly radiosensitive. For localized disease, radiotherapy is the most appropriate treatment for organ preservation. It should be noted that, in patients of reproductive age, there is a risk of infertility with definitive radiation to the bladder secondary to the proximity of nearby reproductive organs. In these cases, maximal resection with TURBT may be the best treatment option when fertility is of concern. Chemotherapy and rituximab are reserved for secondary, recurrent, or disseminated disease \[[@B16]--[@B18], [@B21]\]. Al-Maghrabi et al. in 2001 identified four patients who received low dose radiotherapy for Stage IAE primary lymphoma of the bladder in a 30-year retrospective study. All four patients are alive and recurrence-free 2--13 years after treatment \[[@B10]\].

When considering radiation as a definitive monotherapy, staging becomes of utmost importance. 18F-FDG PET/CT, pelvic MRI, and bone marrow biopsy are used for initial disease staging and to rule out disseminated disease \[[@B1], [@B2], [@B10], [@B12]\]. As there was no evidence of disease in our patient\'s imaging work-up and post-TURBT cystoscopy, she was presented with observation with cystoscopy at 3-4-month intervals versus radiation therapy with less frequent cystoscopy and imaging. The optimal follow-up strategy for patients with lymphoma of the bladder remains unknown. In our practice, once the patient achieves complete response on posttreatment imaging, no further imaging is indicated. Urine cytology should be performed at each visit and annual cystoscopy should be performed for the first 2-3 years.

In conclusion, primary MALT lymphoma of the bladder represents a rare malignancy with excellent prognosis if detected at an early stage. For early stage disease, definitive radiation represents an excellent treatment modality with a minimal side-effect profile.
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![(a) Low power images of H&E stain show infiltration of the bladder wall by small plasmacytoid lymphocytes. (b) High power images of H&E stain show infiltration of the bladder wall by small plasmacytoid lymphocytes. (c) CD20 stain shows positive cells. (d) PAX-5 stain shows diffusely positive cells.](CRIHEM2015-934374.001){#fig1}

![3D conformal radiation therapy of MALT lymphoma of the bladder with dose distributions depicted in the sagittal (a), axial (b), and coronal (c) planes.](CRIHEM2015-934374.002){#fig2}

###### 

Characteristics of reported cases of primary MALT lymphoma of the bladder on PubMed as of June 2015.

  Author                                 Age   Sex      Presenting symptom                                   Treatment                                           Follow-up (Months)   Outcome
  -------------------------------------- ----- -------- ---------------------------------------------------- --------------------------------------------------- -------------------- -------------------------------
  Hughes et al., \[[@B34]\]              81    Female   Hematuria                                            Diathermy TURBT                                     12                   NED
  Ando et al., \[[@B16]\]                77    Female   Urinary retention                                    TURBT                                               36                   NED
  Kempton et al., \[[@B43]\]             64    Female   *∗*                                                  Partial cystectomy                                  144                  Died of unknown cause
  Fernandez Acenero et al., \[[@B44]\]   73    Female   Dysuria, Back pain                                   Chemotherapy                                        8                    Died of unknown cause
  Fernandez Acenero et al., \[[@B44]\]   50    Female   Fever                                                Chemotherapy                                        60                   NED
  Fernandez Acenero et al., \[[@B44]\]   75    Female   Hematuria, dysuria and Breast carcinoma              Chemotherapy                                        9                    NED
  Gallardo et al., \[[@B42]\]            70    Female   Hematuria, Dysuria, Malaise and weight loss          Chemotherapy                                        24                   NED
  Morita et al., \[[@B27]\]              68    Female   persistent interstitial cystitis                     Chemotherapy \[Rituximab\]                          *∗*                  NED
  Wazait et al., \[[@B39]\]              65    Female   Hematuria, dysuria and recurrent UTI\'s              Chemotherapy \[CHOP\]                               36                   NED
  Hughes et al., \[[@B34]\]              77    Male     Hematuria                                            Chemotherapy \[ChID\]                               48                   NED
  Hughes et al., \[[@B34]\]              28    Male     Hematuria                                            Chemotherapy \[ChIVP\]                              120                  NED
  Kakuta et al., \[[@B17]\]              84    Female   General fatigue and weight loss                      Chemotherapy \[R-CHOP\]                             *∗*                  *∗*
  Sen et al., \[[@B31]\]                 31    Female   Incidental finding - Pregnancy                       Postpartum Chemotherapy                             *∗*                  *∗*
  Kempton et al., \[[@B43]\]             79    Female   *∗*                                                  Radiation                                           24                   Died of Myocardial infarction
  Al-Maghrabi et al., \[[@B10]\]         64    Female   Hematuria, and recurrent UTI                         Radiation                                           156                  NED
  Al-Maghrabi et al., \[[@B10]\]         69    Female   Treatment resistant UTI                              Radiation                                           60                   NED
  Al-Maghrabi et al., \[[@B10]\]         72    Female   Hematuria and recurrent UTI                          Radiation                                           36                   NED
  Al-Maghrabi et al., \[[@B10]\]         62    Male     Hematuria                                            Radiation                                           24                   NED
  Tsang et al., \[[@B38]\]               *∗*   *∗*      *∗*                                                  Radiation                                           *∗*                  NED
  Tsang et al., \[[@B38]\]               *∗*   *∗*      *∗*                                                  Radiation                                           *∗*                  NED
  Tsang et al., \[[@B38]\]               *∗*   *∗*      *∗*                                                  Radiation                                           *∗*                  NED
  Hughes et al., \[[@B34]\]              76    Female   Hematuria                                            Radiation                                           24                   NED
  Hughes et al., \[[@B34]\]              66    Female   Recurrent UTI                                        Radiation                                           *∗*                  Deceased
  Takahara et al., \[[@B25]\]            85    Female   Hematuria                                            Radiation                                           *∗*                  NED
  Hatano et al., \[[@B15]\]              84    Female   Hematuria and recurrent UTI                          Radiation                                           12                   NED
  Kempton et al., \[[@B43]\]             73    Female   *∗*                                                  Fulguration and Radiation                           120                  Died of unknown cause
  Kempton et al., \[[@B43]\]             27    Female   *∗*                                                  Tumor resection and Radiation                       480                  Died of fibrosarcoma
  Kempton et al., \[[@B43]\]             45    Male     *∗*                                                  Segmental resection and Radiation                   312                  Died of unknown cause
  Kempton et al., \[[@B43]\]             50    Female   *∗*                                                  Segmental resection and Radiation                   240                  NED
  Ueno et al., \[[@B33]\]                64    Female   Incidental finding                                   TURBT and Radiation                                 19                   Recurrence Stomach
  Haddad-lacle et al., \[[@B22]\]        54    Male     Low back pain, incidental bladder mass               TURBT and Radiation                                 36                   NED
  Wazait et al., \[[@B39]\]              70    Female   Hematuria                                            TURBT-1 yr recurrence, Chemotherapy on recurrence   60                   NED
  Szopiński et al., \[[@B30]\]           17    Female   Incidental finding                                   TURBT and Chemotherapy                              24                   NED
  Maninderpal et al., \[[@B28]\]         65    Female   Chronic suprapubic mass, nausea and feeling unwell   TURBT and Chemotherapy                              3                    Died of Sepsis
  Matsuda et al., \[[@B3]\]              78    Female   Refractory Cystitis and renal dysfunction            TURBT and Chemotherapy \[rituximab\]                *∗*                  *∗*
  Kawakami et al., \[[@B40]\]            27    Male     *∗*                                                  Radiation and Chemotherapy \[doxorubicin\]          18                   NED
  Tasu et al., \[[@B41]\]                75    Female   Hematuria                                            Radiation and Chemotherapy \[cyclophosphamide\]     36                   NED
  Painemal et al., \[[@B37]\]            70    Female   Hematuria, Dysuria, Malaise and weight loss          Radiation and Chemotherapy                          48                   NED
  Hughes et al., \[[@B34]\]              82    Female   Hematuria                                            Radiation + Chemotherapy \[ChIVP\]                  *∗*                  Deceased
  Terasaki et al., \[[@B19]\]            64    Female   General malaise and anemia                           Radiation and Chemotherapy \[Rituximab\]            14                   NED
  Mizuno et al., \[[@B24]\]              72    Female   Hematuria and recurrent cystitis                     TURBT, Radiation and Chemotherapy \[rituximab\]     *∗*                  *∗*
  Bacalja et al., \[[@B23]\]             48    Male     Incidental finding                                   TURBT, Radiation and Chemotherapy \[R-CHOP\]        5                    Remission
  Mayer et al., \[[@B26]\]               70    Male     Bladder mass with scalp metastasis                   Chemotherapy and Radiation for scalp and brain      14                   Died of Brain Metastasis
  van den Bosch et al., \[[@B36]\]       59    Male     Hematuria                                            triple therapy \[patient denied radiation\]         36                   NED
  Fujimura et al., \[[@B32]\]            69    Female   Hematuria and anemia                                 Antibiotics and *H. pylori* therapy                 24                   NED
  Terada, \[[@B29]\]                     88    Female   Hematuria                                            Antibiotics                                         6                    Markedly reduced tumor size
  Lucioni et al., \[[@B20]\]             72    Female   Persistent dysuria                                   Antibiotics                                         6                    NED
  Bates et al., \[[@B11]\]               66    Female   Bladder mass                                         *∗*                                                 12                   NED
  Bates et al., \[[@B11]\]               79    Female   Hematuria                                            *∗*                                                 *∗*                  *∗*
  Bates et al., \[[@B11]\]               59    Female   Untreated solid necrotic tumor                       *∗*                                                 36                   NED
  Kröber et al., \[[@B35]\]              57    Male     Obstructive dysuria                                  *∗*                                                 *∗*                  *∗*
  Takahashi et al., \[[@B25]\]           71    Female   Hematuria                                            *∗*                                                 *∗*                  *∗*

^*∗*^Authors do not have access to this information.

CHOP: cyclophosphamide, hydroxydaunorubicin, vincristine, and prednisone.

R-CHOP: cyclophosphamide, hydroxydaunorubicin, vincristine, prednisone, and rituximab.

ChlVP: chlorambucil, vincristine, and prednisolone.

TURBT: transurethral resection of bladder tumors.

NED: no evidence of disease.
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